I do think this is the year for Rexista. Lots of stars lining up like government pressure for abuse deterrent opiods, Purdue litigation resolving and lastly they are nearly ready to file the NDA. Then we have the backlog of ANDAs. I would not be surprised to hear a few ANDA approvals this year as well.
Actually, although I was suspect, I think he is just a frustrated long that is down a lot on his investment. I am sure he had hoped that going into data the PPS would rise. But with market conditions, that is not happening. It can make one wonder if the price reflects the PH3 trial going bad??? Although I do not believe that to be the case, I now understand how he could feel that way- especially if he has a lot tied up in CYTR.
Although a partnership is possible before filing the NDA, I personally believe they will fill without a partner. I know many others believe they will partner prior to filing, but I believe they fully intend to file without partnering.
In the December 2015 presentation(available on the website) they say the following:
Results indicate that aldoxorubicin can cross the blood-brain barrier
I gave you a thumbs up for that post. Some on Twitter have taken the opinion that in a bad market, speculative bios can even sink below cash value. So as you say, this drop may be nothing more than the market. I personally am just going to wait and see how PH3 plays out. Like I said, it will be feast or famine.
I read your post before it was taken down. Thank you for responding. I guess this comes down to how PH3 STS turns out. Yes, there certainly is a chance that the trial does not pan out and it tanks even further. Those are the inherent risks with these types of investments- it can be feast or famine. I do believe you may have invested in this company without proper evaluation of the company. I am guessing a lot of the info you mentioned was available prior to buying. One advantage I feel Aldox has dosing until progression. I do believe some patients in the trial will respond exactly the same as those that take Dox. However, I think some that could continue to benefit from Dox past its maximum dose(about a time period of 4 months) will continue to see benefit from dosing until progression of Aldox. Good luck.
telmeafbl- Sounds like you do some seriously good DD. Being an oncologist you must really evaluate and get a good idea what bio companies and products you are investing your hard earned money in... Or do you just read the latest pump piece on Seeking Alpha and go all in?
Just remember this, if they deliver statistically significant positive data on PFS in the PH3 trial we have nothing to worry about.
You are probably right. I guess an oncologist who came to the YMB complaining he was duped by Dream Team on a speculative chemotherapy drug company would really look like an idiot. Likely not an Oncologist... Out of curiosity I looked him up on Twitter and he follows only 8 people and has never made a post. One of the people he follows is Adam Feuerstein. Another is Cytrx. The one reason I actually thought he was a real person was a year ago he got on here and said he lived in the same town as me and even pointed out an area- right near the University Hospital. Yep, sounds like he is indeed a fraud with an account only created to complain about CYTR.
Did you buy only on the basis of the Dream Team? You are an Oncologist- so highly educated and maybe even considered an expert in the area of chemotherapy- what were your reasons for buying CYTR?
Compare GILD's earning multiple to other bios out there like CELG- pretty crazy. Market really thinks GILD cannot grow anymore at all. Should be an interesting year for GILD. They will buy another company when the time is right. At this price, share buyback is a way to deploy all that profit until they are sure of the right company. In the near term, market sentiment will hold GILD down but they are a great company and they will rebound.
Yes, CYTR management has really kept all these trials on schedule. For as much heat as management takes, they sure do publish and meet schedule dates. You cannot say that about many companies out there. They are getting things done.
In the December 2015 corporate presentation on CYTR's website, it says they would present data 1H2016. So nothing has changed. They are on a calendar year so that means by end of June 2016. I do think they probably do have a good idea of how the data is coming in. Hopefully later means better.
drphilospher is 100% right and this question has been answered at least 2 or 3 times if not 5 or 6. Compassionate use is indeed available.